Adaptive clinical trials can help reduce risk for sponsors by allowing sample sizes to increase if initial treatment assumptions are incorrect. The document describes how the East software allows users to design adaptive trials that preserve statistical validity while enhancing success. East users can simulate different design scenarios to determine optimal interim analysis points and ensure type 1 error control as required by regulators. This helps de-risk investment and boost power if initial power calculations are insufficient.